Drug Approved to Treat DMD Gets More Expensive
A new drug to treat Duchenne muscular dystrophy (DMD) has been around for decades in Europe, but will come to the market in the United States with a much bigger price tag. According to The Wall Street Journal, Marathon Pharmaceuticals LLC will bring deflazacort to the United States for $89,000 a year. The corticosteroid was approved Thursday to treat DMD. The drug isn’t a cure, however; instead, it improves muscle strength for boys affected by the disease. Americans have been importing deflazacort from the United Kingdom at a much lower price. The article highlights one mother who pays about $1600 annually.
Why Drug Price Hikes Can Be Necessary
The list price of deflazacort is a 6000% price increase over the price in Europe or Canada. However, Matthew Herper at Forbes explains why this price hike was necessary: because deflazacort had never been approved in the United States, Marathon had to get it approved, which meant conducting 17 clinical and preclinical trials. In the end, the high cost of the drug is necessary to pay for the cost of getting FDA approval and still making a profit.
The ACA’s Taxes
The Associated Press took a look at the taxes imposed by the Affordable Care Act that will bring in about $1.1 trillion in revenue over 10 years. For instance, the 3.8% tax on investment income over a certain threshold would bring in $223 billion in revenue. Overall, there are more than 10 individual taxes listed out by the AP that have helped pay for expanding health coverage. However, Republican efforts to replace or even alter the law could significantly affect this estimated revenue over the next decade.
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Integrated CKD Care Model Cuts ED Visits by 30%, Boosts Specialized Treatment
April 21st 2025An analysis of an interdisciplinary care model for managing chronic kidney disease (CKD) shows hospital admissions dropped by 26% and emergency department (ED) visits decreased by 30% after clinic initiation.
Read More